Lilly Licenses OSI Glucokinase Activator Program For Type 2 Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
The nearly $400 million deal gives Lilly exclusive rights to OSI’s GKA drugs, including a lead compound in Phase I studies.